ANG Lifesciences India logo

ANG Lifesciences India financials: balance sheet, profit and loss, cash flow

BSE: 540694Pharmaceuticals & BiotechnologySmall Cap

ANG Lifesciences India Limited · Face value ₹10 · Listed Sep 2017
Last close ₹32.87up ₹0.78 (2.43%)

Share price at the BSE close on 2 Nov 2026. Previous close ₹32.09.

2 Nov: open ₹32.09, high ₹34.50, low ₹31.00

52-week range of traded prices to 2 Nov 2026
₹17.63Low, 30 Mar 2026₹49.69High, 25 Jun 2026
Market cap
₹43 Cr3,715th largest listed
P/E
Lossover the last 12 months
P/B
0.81
Dividend yield
Nonein the last 12 months
ROE
−22.8%
ROCE
−6.3%
Debt to equity
1.47
Volume, BSE
2,769

ANG Lifesciences India's financial statements for the 9 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

9 years at a glance

₹ crore, years to March.ANG Lifesciences India annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
763.7Mar 181225.619Mar 191276.118Mar 201547.040Mar 213494061Mar 22207−0.753Mar 23131−8.656Mar 2490−1068Mar 2592−4.765Mar 26
Peak revenue ₹349 Cr, year to Mar 2022; lowest ₹76 Cr, year to Mar 2018A loss in 4 of the 9 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
18.7%−11.5%9.3%18.7%5.3%6.9%−2.0%7.2%4.9%4.6%4.8%4.6%11.4%−0.3%−6.6%−11.5%−5.2%Mar 18Mar 20Mar 22Mar 24Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue92
  2. Materials and goods−58
  3. Employee costs−14
  4. Other expenses−12
  5. Operating profit6.6
  6. Depreciation−6.1
  7. Other income+0.7
  8. One-off items0.0
  9. Finance costs−6.4
  10. Profit before tax−5.2
  11. Tax+0.5
  12. Net profit−4.7

What the company owns

  • Plant, investments and other assets₹88 Cr
  • Receivables₹65 Cr
  • Inventory₹33 Cr
  • Cash and bank₹4 Cr

What pays for it: net worth and liabilities

  • Borrowings₹65 Cr
  • Net worth₹62 Cr
  • Owed to suppliers₹40 Cr
  • Other liabilities₹23 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.ANG Lifesciences India quarterly results

₹ croreMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 MayJun 2026Twelve monthsFiled 14 Aug
Revenue from operations76122127154349207131909281
69–––284196122928578
Materials and goods bought53888910423014787615851
Employee costs6–––182016141414
Other expenses10–––352919171212
Operating profit before depreciation7–––65119−273
Operating margin9.3%–––18.7%5.3%6.9%−2.0%7.2%4.1%
Materials, % of revenue69.6%–––66.0%71.0%66.4%67.4%63.6%63.5%
Employee costs, % of revenue7.4%–––5.3%9.8%12.1%16.1%15.7%17.7%
Other expenses, % of revenue13.8%–––10.1%13.9%14.6%18.5%13.5%14.8%
Depreciation and amortisation1–––598666
Operating profit after depreciation6–––6031−81−3
Other income10011101211
Finance costs22338109767
Profit before one-off items and tax58810532−7−13−5−9
One-off items––––00−2000
Profit before tax58810532−9−13−5−9
12231330−30−1
Net profit466740−1−9−10−5−7
Other comprehensive income––––010000
Total comprehensive income––––400−8−10−5−7
Net margin4.9%4.6%4.8%4.6%11.4%−0.3%−6.6%−11.5%−5.2%−9.1%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
2935428386776762
Share capital5551013131313
Reserves2429367372645449
1918406153566865
425192154146126125125
10911312114163
8194144269253217209190
2121288783575853
6073116182168158147133
Net debt1415365447506461
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
−13.727.426.0−13.1−2.313.7
−7.628.029.40.31.913.8
−22.1−39.99.0−8.33.16.7
Receivables−12.7−42.319.97.93.9−0.7
Inventories−9.3−9.9−8.23.2−3.64.8
Payables14.321.2−4.1−3.5−3.2−15.4
Other working capital−14.4−8.91.4−15.96.118.0
Tax paid−3.1−0.6−3.4−13.4−4.20.0
Interest paid−3.00.00.00.00.00.0
Capital spending4.239.310.45.44.14.1
Free cash flow−18.0−12.015.6−18.6−6.49.6
−7.7−42.5−9.320.0−1.6−3.3
21.715.3−16.7−7.03.9−10.2
Dividends paid0.01.00.00.00.00.0
Shares bought back–0.00.00.00.00.0
Shares issued0.00.02.00.00.00.0
Net change in cash0.30.2−0.1−0.10.00.2
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.ANG Lifesciences India dividend history

₹ per shareMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
₹2.87₹4.36₹4.70–₹30.81–−₹6.48−₹7.86−₹3.52
As stated that year₹7.18₹10.90₹11.76–₹38.51–−₹6.48−₹7.86−₹3.52
₹2.87₹4.36₹4.70–₹30.81–−₹6.48−₹7.86−₹3.52
––––₹0.80––––
–₹22.20₹26.67₹32.09₹64.42₹65.50₹59.02₹51.16₹47.65
Dividend payout––––2.6%––––
Shareholder yield–––0.0%0.4%−2.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)2925164424399593024
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from. As stated that year and earnings per share are left blank for the year to Mar 2021: the earnings per share is stated as 0 while the period's profit or loss comes to at least half a paisa a share, so the 0 stands in for a figure the filing does not give. As stated that year and earnings per share are left blank for the year to Mar 2023: the earnings per share stated has the opposite sign to the profit stated beside it, so it is not shown.

Ratios

Standalone, years to March.ANG Lifesciences India PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 30 May
Revenue growth–60.0%4.2%21.7%125.9%−40.6%−36.5%−31.6%1.9%
Operating profit growth–––––−83.0%−17.6%––
Net profit growth–51.7%7.9%15.3%465.1%––––
Earnings per share growth–51.8%7.9%––––––
–19.6%19.3%18.5%63.5%−0.8%−10.6%−14.4%−7.3%
––−0.4 pts−0.8 pts45.0 pts−64.3 pts−9.9 pts−3.7 pts7.1 pts
From the net margin––0.7 pts−1.0 pts27.7 pts−65.3 pts−15.3 pts−8.0 pts7.9 pts
From asset turnover––−0.7 pts−1.9 pts14.0 pts0.9 pts4.8 pts4.6 pts−0.6 pts
From borrowing––−0.3 pts2.1 pts3.4 pts0.1 pts0.7 pts−0.3 pts−0.3 pts
Return on capital employed––––41.5%1.8%1.0%−6.0%0.4%
Cash conversion–––−195.2%69.0%––––
Interest cover3.7–––7.60.20.1–0.1
Debt to equity–0.650.530.960.730.620.721.011.04
Receivable days–125133139104138192264260
Inventory days–2741684693143228207
Payable days––––105154244334250
Cash conversion cycle, days––––457792158217
Working capital days–779012673103211293275
Asset turnover–1.501.451.301.690.790.560.420.46
Assets per rupee of net worth–2.812.763.123.303.082.892.963.09
Sales per rupee of plant–5.865.996.414.242.632.461.711.95
Capital spending to depreciation––––7.691.230.700.660.68
Plant being built, % of plant in use––––0.0%0.0%0.0%––
Interest cover is left blank for the year to Mar 2025: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−2.4%
Cash from operations against operating profit
207.5%
Measure10 years5 years3 years
Revenue growth, yearly rate–−9.9%−23.8%
Return on equity, average–6.1%−10.8%
Return on capital employed, average–7.8%−1.5%
Operating margin, average–7.2%4.0%
Net margin, average0.7%−2.4%−7.7%
Asset turnover, average–0.790.48
Cash conversion cycle, days, average–118156
Interest cover, average–2.00.1
Debt to equity, average–0.830.93

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations51.7−1.713.7
Cash from investing−36.815.1−3.3
Cash from financing−14.7−13.3−10.2
Capital spending63.513.74.1
Dividends paid1.00.00.0
Shares bought back0.00.00.0
Shares issued for cash2.00.00.0
Borrowings repaid0.00.00.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––3–––
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––26.59––––
Receivables growth less revenue growthOur threshold 0 percentage points––6.125.80−57.34––––
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––51.7575.65−69.81––––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––4.5313.583.68––––
Effective tax ratePublished threshold 17.16 per cent24.8130.3327.4930.69–––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
24 Aug 2026Infomerics Valuation and Ratings Private LimitedLong Term RatingIVR C (INC)Review, OtherNegative49.16
24 Aug 2026Infomerics Valuation and Ratings Private LimitedShort Term RatingIVR A4 (INC)Review, Re-affirm20
29 Sep 2025Infomerics Valuation and Ratings Private LimitedLong Term Bank FacilitiesLong-term scaleIVR B/INCReview, DowngradeNegative49.16
29 Sep 2025Infomerics Valuation and Ratings Private LimitedShort Term Bank FacilitiesShort-term scaleIVR A4/INCReview, Re-affirm20
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.